Exelixis

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exelixis reports robust Q4 performance, eyes pipeline expansion in 2023

Exelixis showed strong revenue growth and strategic wins in Q4 2022.
The company faces challenges with net losses and gross to net expectations.
Opportunities lie in pipeline advancement, zanzalintinib development, and new business activities.
Overall, Exelixis remains focused on growth and innovation in the pharmaceutical sector.

Exelixis reports strong Q1 earnings, advances promising pipeline programs

Exelixis showcased robust financials and a promising pipeline in Q1, driven by strong CABOMETYX performance and R&D advancements.
Challenges include gross to net impact and delays in share repurchase program purchases, with key decisions pending on XL102 progress.
Opportunities lie in expanding Phase 3 trials, focusing on unmet needs, and maintaining a strategic approach to asset prioritization for future growth.

Exelixis reports robust Q2 earnings, advances pipeline for growth

Exelixis delivered a strong Q2 performance with significant revenue and income figures, driven by the success of CABOMETYX and ongoing R&D efforts.
The company's market leadership, legal resolution with Teva, and commitment to innovation position it well for future growth and competitive advantage.
While facing challenges in program decision-making and market penetration, Exelixis has opportunities in pipeline advancement, regulatory discussions, and investor engagement.
Overall, Exelixis remains focused on its mission to help cancer patients, with a positive outlook and strategic initiatives in place for continued success.

Exelixis reports strong Q3 earnings, faces guidance challenges and growth opportunities

Exelixis had a strong Q3 2023 with robust revenue growth from CABOMETYX and ongoing operational support.
The company faces challenges in financial guidance adjustments and questions on FDA expectations and legal proceedings.
Opportunities lie in potential growth for CABOMETYX, advancing pipeline assets, and expanding into new indications.
Overall, Exelixis remains focused on innovation, collaboration, and supporting cancer patients with upcoming R&D Day excitement.

Exelixis reports robust 2023 performance, eyes growth through collaborations

Exelixis had a strong financial performance in 2023, driven by the cabozantinib franchise and strategic initiatives.
While facing challenges such as access to therapies and treatment variations, the company is well-positioned for growth.
Opportunities lie in collaborations, regulatory progress, and innovative drug development, positioning Exelixis for future success.

Exelixis reports strong Q1 earnings, focuses on pipeline advancement

Exelixis had a robust Q1 2024 with revenue and demand growth for Cabozantinib franchise.
Company is focused on advancing new indications, returning capital to shareholders, and pipeline development.
Challenges include study criteria, market capture, and capital allocation decisions.
Exciting opportunities lie in Zanza's potential, new combinations, and market growth prospects.

Exelixis excels in Q2 with cabozantinib driving revenue growth

Exelixis delivered a strong Q2 performance driven by cabozantinib franchise. Despite challenges in a competitive landscape, the company's focus on pipeline assets and commercial success presents growth opportunities. With increased revenue guidance and strategic initiatives, Exelixis is poised for continued success.

Exelixis excels in Q3 2024 with revenue growth and increased guidance

Exelixis delivered a strong performance in Q3 2024, marked by revenue growth, profitability, and increased guidance for the full year. The company's financial stability, strategic focus on oncology, and strong cash position provide a solid foundation for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

The biotech announced a shareholder-pleasing bit of financial engineering. This will total as much as $550 million by the end of this year.

Why Exelixis Stock Leaped More Than 4% Higher Today

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the company's Board of Directors has authorized the repurchase of up to $550 million of the company's common stock before the end of 2023.

Exelixis Announces $550 Million Share Repurchase Program

CRISPR Therapeutics

Intellia Therapeutics

2023 could be a landmark year for CRISPR Therapeutics. Exelixis has solid fundamentals, plus plenty of upside potential.

3 Beaten-Down Stocks That Could Soar This Year

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, March 16, 2023 at 10:00 a.m. ET / 8:00 a.m. MT / 7:00 a.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.

Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

Disney

Alphabet

Innovative Industrial Properties

The widely followed Nasdaq Composite, which led Wall Street to new highs in 2021, was clobbered last year. Based on history, bear markets represent perfect buying opportunities for long-term investors.

Nasdaq Bear Market: 5 Stunning Growth Stocks You'll Regret Not Buying on the Dip

Snap

Exelixis' exciting oncology platform can lead to new products and higher revenue. Snap's popularity among younger users remains a major long-term tailwind.

2 Stocks to Buy With Less Than $20

Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).

Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal

Exelixis Inc. EXEL, -1.66% shares fell in the extended session Thursday after the biotech drug maker said a late-stage clinical trial of its kidney cancer drug treatment did not meet its endpoint. Exelexis shares fell 6% after hours, following a 1.7% decline to close the regular session at $17.18.

Exelexis stock falls as kidney cancer drug trial fails

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival (PFS).

Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

Exelixis has strong revenue growth and a positive outlook. Past success with a growing industry ensures demand for its products.

Exelixis Inc.: Cancer Crusader With A Bright Future

CrowdStrike

Mastercard

Pinterest

A 33% plunge in the growth-dependent Nasdaq Composite is the perfect excuse for investors to buy into these innovative businesses.

Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip

Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.

Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805

ALAMEDA, Calif. & ROTTERDAM, The Netherlands--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the U.S. Food and Drug Administration (FDA) has cleared Sairopa's Investigational New Drug (IND) Application to evaluate the safety and pharmacokinetics of ADU-1805 in adults with advanced solid tumors.

Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.

Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx

The headline numbers for Exelixis (EXEL) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics

Exelixis, Inc. (NASDAQ:EXEL ) Q4 2022 Results Conference Call February 7, 2023 5:00 PM ET Company Participants Susan Hubbard - EVP, Public Affairs and IR Mike Morrissey - President and CEO Chris Senner - CFO P.J. Haley - EVP, Commercial Vicki Goodman - Chief Medical Officer Peter Lamb - Chief Scientific Officer Conference Call Participants Asthika Goonewardene - Truist Securities Michael Schmidt - Guggenheim Geoffrey Weiner - Credit Suisse Jason Gerberry - Bank of America Andy Hsieh - William Blair Etzer Darout - BMO Capital Markets Yaron Werber - Cowen Peter Lawson - Barclays Silvan Tuerkcan - JMP Securities Mike King - EF Hutton Operator Good day, ladies and gentlemen, and welcome to the Exelixis Fourth Quarter and Full Year 2022 Financial Results Conference Call.

Exelixis, Inc. (EXEL) Q4 2022 Earnings Call Transcript

Exelixis (EXEL) delivered earnings and revenue surprises of 40% and 1.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Reports Q4 Loss, Tops Revenue Estimates

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones. “Exelixis had a productive fourth quarter and full year 2022 as we continued to grow the cabozantinib commercial franchise and significantly advanced our growing product pipeline,” said Michael M.

Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Editas Medicine

Ironwood Pharma

All three healthcare stocks are showing solid long-term potential.

3 No-Brainer Stocks to Buy Right Now for Less Than $25

ALAMEDA, Calif.--( BUSINESS WIRE )--Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 7, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website.

Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

ALAMEDA, Calif.--( BUSINESS WIRE )--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. (MSN), Action No. 19-2017 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis' favor, rejecting MSN's challenge to the cabozantinib compound patent (U.S. 7,579,473). The District Court's decision follows an earlier Stipulation and Order of October 1, 2021, that MSN's proposed generic cabozantinib product (Abbreviated New Drug Application [ANDA] No. 213878) infringes the '473 patent.

Exelixis Announces Update on Patent Litigation with MSN Laboratories

Exelixis' CABOMETYX is hitting on all cylinders. Exelixis has an interesting and highly cabozantinib-centric pipeline.

Exelixis: Building On A Blockbuster

AbbVie

CureVac B.V

Incyte

Pfizer

Sarepta Therapeutics

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.

7 Biotech Stocks That Will Make You Rich in 10 Years

TOKYO , Jan. 10, 2023 /PRNewswire/ -- Ajinomoto Co., Inc. ("Ajinomoto Co.") today announced a license agreement with Exelixis, Inc. ("Exelixis") to incorporate AJICAP®, Ajinomoto Co.'s proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate (ADC) programs. Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers.

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.

News for Exelixis Stock (EXEL)